Harvard Catalyst Profiles

Contact, publication, and social network information about Harvard faculty and fellows.

Alice Tsang Shaw, Ph.D., M.D.

Co-Author

This page shows the publications co-authored by Alice Shaw and Mark Awad.
Connection Strength

3.335
  1. Successful desensitization of two patients with ALK-positive lung cancer and hypersensitivity to crizotinib. J Thorac Oncol. 2014 Nov; 9(11):1726-8.
    View in: PubMed
    Score: 0.613
  2. ALK inhibitors in non-small cell lung cancer: crizotinib and beyond. Clin Adv Hematol Oncol. 2014 Jul; 12(7):429-39.
    View in: PubMed
    Score: 0.599
  3. Acquired resistance to crizotinib from a mutation in CD74-ROS1. N Engl J Med. 2013 09 19; 369(12):1173.
    View in: PubMed
    Score: 0.567
  4. Acquired resistance to crizotinib from a mutation in CD74-ROS1. N Engl J Med. 2013 Jun 20; 368(25):2395-401.
    View in: PubMed
    Score: 0.555
  5. BRAF Mutation Class and Clinical Outcomes-Response. Clin Cancer Res. 2019 05 15; 25(10):3189.
    View in: PubMed
    Score: 0.210
  6. Impact of BRAF Mutation Class on Disease Characteristics and Clinical Outcomes in BRAF-mutant Lung Cancer. Clin Cancer Res. 2019 01 01; 25(1):158-165.
    View in: PubMed
    Score: 0.200
  7. Tyrosine kinase gene rearrangements in epithelial malignancies. Nat Rev Cancer. 2013 Nov; 13(11):772-87.
    View in: PubMed
    Score: 0.143
  8. ALK rearrangements are mutually exclusive with mutations in EGFR or KRAS: an analysis of 1,683 patients with non-small cell lung cancer. Clin Cancer Res. 2013 Aug 01; 19(15):4273-81.
    View in: PubMed
    Score: 0.139
  9. Pemetrexed-based chemotherapy in patients with advanced, ALK-positive non-small cell lung cancer. Ann Oncol. 2013 Jan; 24(1):59-66.
    View in: PubMed
    Score: 0.131
  10. Clinical activity of programmed cell death 1 (PD-1) blockade in never, light, and heavy smokers with non-small-cell lung cancer and PD-L1 expression =50. Ann Oncol. 2020 03; 31(3):404-411.
    View in: PubMed
    Score: 0.055
  11. STK11/LKB1 Mutations and PD-1 Inhibitor Resistance in KRAS-Mutant Lung Adenocarcinoma. Cancer Discov. 2018 07; 8(7):822-835.
    View in: PubMed
    Score: 0.049
  12. Patient-derived models of acquired resistance can identify effective drug combinations for cancer. Science. 2014 Dec 19; 346(6216):1480-6.
    View in: PubMed
    Score: 0.038
  13. The ALK inhibitor ceritinib overcomes crizotinib resistance in non-small cell lung cancer. Cancer Discov. 2014 Jun; 4(6):662-673.
    View in: PubMed
    Score: 0.037
Connection Strength
The connection strength for co-authors is the sum of the scores for each of their shared publications.

Publication scores are based on many factors, including how long ago they were written and whether the person is a first or senior author.
Funded by the NIH National Center for Advancing Translational Sciences through its Clinical and Translational Science Awards Program, grant number UL1TR002541.